Teriparatide

also known as Forteo · PTH 1-34 · TPTD · Forsteo · rhPTH 1-34 · Synthetic Human Parathyroid Hormone 1-34 · AK159 · hPTH 1-34 · +7 more

Protein / enzyme biologic

Developed for: osteoporosis · postmenopausal osteoporosis · hypoparathyroidism · disease of bone structure · spinal cord injury · autosomal dominant hypocalcemia · bone resorption disease · chronic kidney disease
+17 more
· chronic renal failure syndrome · osteogenesis imperfecta · periodontitis · premenopausal osteoporosis · psoriasis · rheumatoid arthritis · secondary hypoparathyroidism due to impaired parathormon secretion · spinal stenosis · spondylolisthesis · spondylosis · anorexia nervosa · autoimmune polyendocrine syndrome type 1 · autosomal dominant hypocalcemia 1 · bone marrow disorder · bone remodeling disease · neurogenic arthropathy · osteoarthritis, knee
Investigated by: Eli Lilly and Company · Entera Bio Ltd. · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Asahi Kasei Therapeutics Corporation · Health Research, Inc. · Massachusetts General Hospital
+85 more
· Ministry of Defence, United Kingdom · Odense University Hospital · Pfenex, Inc · Thomas J. Schnitzer · University Hospital, Linkoeping · University of California, San Francisco · University of East Anglia · University of Michigan · Aalborg University Hospital · Amgen · Assistance Publique - Hôpitaux de Paris · Bio Sidus SA · Brigham and Women's Hospital · Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK) · Columbia University · Congressionally Directed Medical Research Programs · Copenhagen University Hospital, Denmark · Darlington Memorial Hospital · Ditte Hansen · Edward Hines Jr. VA Hospital · Esbjerg Hospital - University Hospital of Southern Denmark · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Fluminense Federal University · Hartmut Malluche, MD · Helen Hayes Hospital · Helsinki University Central Hospital · Hospital for Special Surgery, New York · Khyber Medical University Peshawar · King Chulalongkorn Memorial Hospital · Leland Graves III, MD · M.D. Anderson Cancer Center · Manhattan Pharmaceuticals · Mayo Clinic · Medical Research Council of Southeast Sweden · Ministry of Health, France · National Heart, Lung, and Blood Institute (NHLBI) · National Institute for Health Research, United Kingdom · National Institute of Dental and Craniofacial Research (NIDCR) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Norfolk and Norwich University Hospitals NHS Foundation Trust · Northwestern University · Nottingham University Hospitals NHS Trust · Novartis · Odense Patient Data Explorative Network · Ohio Orthopedic Center of Excellence · Papageorgiou General Hospital · Paul F Netzel · Peking Union Medical College Hospital · Peking University Third Hospital · Pfizer · Post Graduate Institute of Medical Education and Research, Chandigarh · Region of Southern Denmark · Rigshospitalet, Denmark · Saint Petersburg State University, Russia · Salubris (Suzhou) Pharmaceutical Co., Ltd. · Seoul National University Bundang Hospital · Shane Burch · Sheffield Teaching Hospitals NHS Foundation Trust · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Shinshu University · Shirley Ryan AbilityLab · Steno Diabetes Center Copenhagen · Susan L. Greenspan · Sygehus Lillebaelt · Syneos Health · The Emmes Company, LLC · The University of Hong Kong · Therapeutics, Inc. · TransPharma Medical · US Department of Veterans Affairs · United States Department of Defense · Universidad de Valparaiso · University of Aarhus · University of Calgary · all 91 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed glucocorticoid-induced osteoporosis 2 milestones
Filed	EU (EMA)	—	glucocorticoid-induced osteoporosis	2019-05-30	“today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) submitted for PF708 (Teriparatide).” alvogen.com ↗ “Lilly filed applications with the FDA and EMEA, respectively, for a supplemental indication for teriparatide” lilly.com ↗
Filed	US (FDA)	—	glucocorticoid-induced osteoporosis	—	“Lilly filed applications with the FDA and EMEA, respectively, for a supplemental indication for teriparatide” lilly.com ↗
Filed osteoporosis 1 milestone
Filed	Other	—	osteoporosis	2019-10-21	“Alvogen has also submitted the marketing authorization application for Teriparatide (PF708) to the Kingdom of Saudi Arabia's Saudi Food and Drug Authority” alvogen.com ↗
Approved Indication not stated 4 milestones
Label expansion	US (FDA)	BONSITY	—	2023-11-16	fda.gov ↗
Label expansions (2)	US (FDA)	FORTEO	—	2009-07-22 – 2020-11-16	fda.gov ↗
Approved	EU (EMA)	Forsteo	—	2003-06-10	europa.eu ↗
Approved	US (FDA)	FORTEO	—	2002-11-26	fda.gov ↗

Trials 96 · started per year

today

US approved 2002

EU approved 2003

199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 19 trials · 1 met primary
Phase 1	NCT07497503	Apr → Sep 2026 overdue	—	Syneos Health	Recruiting	No outcome recorded
Phase 1	NCT05965167	May 2023 → Feb 2026	disease of bone structure, hypoparathyroidism, osteoporosis	Entera Bio Ltd.	Completed	No outcome recorded
Phase 1	NCT02656810	Dec 2015 → Jul 2016	osteoporosis	Pfenex, Inc	Completed	No outcome recorded
Phase 1	NCT02571140	Oct 2013 → Aug 2017	—	Entera Bio Ltd.	Completed	No outcome recorded
Phase 1	NCT01935479	Aug 2013 → Feb 2014	osteoporosis	Asahi Kasei Therapeutics Corporation	Completed	No outcome recorded
Phase 1	NCT01551602	Mar → Sep 2012	osteoporosis	Asahi Kasei Therapeutics Corporation	Completed	No outcome recorded
Phase 1	NCT01250145	Nov 2010 → May 2011	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT00676312	May → Aug 2008	postmenopausal osteoporosis	Novartis	Completed	No outcome recorded
Phase 1	NCT00277706	Aug 2004 → Jul 2009	bone resorption disease, periodontitis	University of Michigan	Completed	Met primary
Phase 1/21 trial
Phase 1/2	NCT06303284	Mar 2027 → Dec 2030 expected	—	University of Calgary	Not yet recruiting	No outcome recorded
Phase 221 trials · 1 met primary · 5 missed
Phase 2	NCT07579936	Apr → Jul 2026 overdue	postmenopausal osteoporosis	Shenzhen Salubris Pharmaceuticals Co., Ltd.	Recruiting	No outcome recorded
Phase 2	NCT04473989	Jun 2021 → Dec 2023	—	Peking University Third Hospital	Unknown	No outcome recorded
Phase 2	NCT02824718	Jun 2017 → May 2020	autosomal dominant hypocalcemia	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT02972424	May 2017 → Mar 2021	osteoporosis	Hospital for Special Surgery, New York	Completed	Missed primary
Phase 2	NCT02152228	Jul 2014 → Jun 2015	hypoparathyroidism	Entera Bio Ltd.	Completed	No outcome recorded
Phase 2	NCT02025179	Jan 2013 → Aug 2015	disease of bone structure, osteoporosis, spinal cord injury	Northwestern University	Completed	No outcome recorded
Phase 2	NCT01679080	Nov 2012 → Jul 2020	osteogenesis imperfecta	University of Aarhus	Terminated	No outcome recorded
Phase 2	NCT01279187	Feb 2011 → Mar 2015	—	University of Michigan	Terminated	No outcome recorded
Phase 2	NCT01171690	Nov 2010 → Dec 2013	secondary hypoparathyroidism due to impaired parathormon secretion	Mayo Clinic	Terminated	Met primary Stop: Business
Phase 2	NCT01225055	Oct 2010 → Aug 2015	disease of bone structure, osteoporosis, spinal cord injury	Thomas J. Schnitzer	Completed	Missed primary
Phase 2	NCT00926380	Jun 2009 → Dec 2016	postmenopausal osteoporosis	Massachusetts General Hospital	Completed	Missed primary
Phase 2	NCT00623974	May 2008 → Jun 2010	—	M.D. Anderson Cancer Center	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00535860	Apr 2008 → Mar 2009	osteoporosis	TransPharma Medical	Completed	No outcome recorded
Phase 2	NCT00593177	Oct 2007 → Jun 2008	psoriasis	Manhattan Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00393380	Sep 2006 → Nov 2009	Hodgkins lymphoma, acute myeloid leukemia, aplastic anemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +2	The Emmes Company, LLC	Terminated	No outcome recorded
Phase 2	NCT00668941	Sep 2005 → Feb 2016	osteoporosis	Helen Hayes Hospital	Unknown	Missed primary
Phase 2	NCT00191867	Feb 2005 → Mar 2006	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00190944	Dec 2004 → Jun 2007	—	Eli Lilly and Company	Completed	Missed primary
Phase 2	NCT00086619	May 2004 → Dec 2009	postmenopausal osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00018447	Nov 1998 → Oct 2003	postmenopausal osteoporosis	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 2	NCT00001304	Oct 1991 → Mar 2014	hypoparathyroidism	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT00697463	Aug 2008 → Jan 2012	premenopausal osteoporosis	Columbia University	Completed	No outcome recorded
Phase 323 trials · 4 met primary · 1 missed
Phase 3	NCT04921124	May → Jul 2021	—	Norfolk and Norwich University Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 3	NCT04750460	Mar 2021 → Feb 2022	hypoparathyroidism, renal osteodystrophy	Saint Petersburg State University, Russia	Completed	No outcome recorded
Phase 3	NCT04196855	Dec 2019 → Jun 2022	—	University of East Anglia	Unknown	No outcome recorded
Phase 3	NCT03133195	May 2017 → Jun 2022	—	King Chulalongkorn Memorial Hospital	Completed	No outcome recorded
Phase 3	NCT03002428	Dec 2016 → May 2018	osteoporosis	Pfenex, Inc	Completed	No outcome recorded
Phase 3	NCT01801397	Mar 2014 → Jun 2016	osteoporosis	University of Zurich	Unknown	No outcome recorded
Phase 3	NCT01473589	Feb 2012 → Dec 2013	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT01473602	Jan 2012 → Nov 2013	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00503399	Jul 2007 → Oct 2010	osteoporosis	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00433160	Jan 2007 → Sep 2008	osteoporosis	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00414973	Dec 2006 → Jul 2008	osteoporosis	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00395538	Oct 2006 → Sep 2017	DiGeorge syndrome, hypoparathyroidism	National Institute of Dental and Craniofacial Research (NIDCR)	Terminated	No outcome recorded
Phase 3	NCT00343252	Jun 2006 → Jun 2009	postmenopausal osteoporosis	Eli Lilly and Company	Completed	Missed primary
Phase 3	NCT00500409	Dec 2005 → Dec 2006	osteoporosis	Virchow Group	Completed	No outcome recorded
Phase 3	NCT00191321	Jul 2004 → Dec 2005	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00065637	Dec 2003 → Sep 2005	osteoporosis	University of California, San Francisco	Completed	No outcome recorded
Phase 3	NCT00532207	Nov 2003 → Dec 2004	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00191893	Sep 2003 → Nov 2006	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00191802	Sep 2003 → Oct 2005	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00543023	Jun 2003 → Aug 2004	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00051558	Nov 2002 → Jul 2006	osteoporosis	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00670501	Aug 1996 → Apr 1999	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00046137	—	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded

Phase 432 trials · 5 met primary · 2 missed
Phase 4	NCT06264609	Feb 2024 → Dec 2029 expected	osteoporosis	Paul F Netzel	Enrolling by invitation	No outcome recorded
Phase 4	NCT06061354	Aug 2023 → Aug 2024	—	Universidad de Valparaiso	Unknown	No outcome recorded
Phase 4	NCT04522622	Dec 2021 → Sep 2026 overdue	chronic kidney disease, heart disorder, renal osteodystrophy	Ditte Hansen	Recruiting	No outcome recorded
Phase 4	NCT03994172	Jul 2019 → Jun 2025	osteoporosis	VA Office of Research and Development	Completed	No outcome recorded
Phase 4	NCT02955056	Oct 2016 → Oct 2017	—	Nottingham University Hospitals NHS Trust	Unknown	No outcome recorded
Phase 4	NCT02156960	May 2014 → May 2015	osteoporosis	Shinshu University	Unknown	No outcome recorded
Phase 4	NCT04241211	Jan 2014 → Dec 2018	—	Seoul National University Bundang Hospital	Unknown	No outcome recorded
Phase 4	NCT02130973	Aug 2013 → Aug 2018	osteoporosis	Health Research, Inc.	Unknown	No outcome recorded
Phase 4	NCT01945788	Jun 2013 → Oct 2014	postmenopausal osteoporosis	Bio Sidus SA	Unknown	No outcome recorded
Phase 4	NCT01753856	Jan 2013 → Jun 2014	osteoporosis	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT01705587	Dec 2012 → Sep 2016	osteoporosis	Susan L. Greenspan	Completed	No outcome recorded
Phase 4	NCT01709110	Oct 2012 → Jul 2016	postmenopausal osteoporosis	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT02090244	Aug 2012 → May 2018	spinal stenosis	University Hospital, Linkoeping	Completed	No outcome recorded
Phase 4	NCT01292252	Aug 2011 → Dec 2015	spondylolisthesis, spondylosis	Shane Burch	Completed	No outcome recorded
Phase 4	NCT01430104	Aug → Dec 2011	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT01400516	Aug 2011 → Jul 2015	rheumatoid arthritis	Brigham and Women's Hospital	Completed	Missed primary
Phase 4	NCT01360424	May 2011 → Nov 2013	osteoporosis	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 4	NCT01293292	Jan 2011 → Aug 2015	osteoporosis	Sheffield Teaching Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT01173081	Jul 2010 → Apr 2014	—	Ohio Orthopedic Center of Excellence	Unknown	No outcome recorded
Phase 4	NCT01105832	Apr 2010 → Feb 2014	—	University Hospital, Linkoeping	Completed	Missed primary
Phase 4	NCT00927186	Jul 2009 → Oct 2010	postmenopausal osteoporosis	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00826228	Jun 2009 → Mar 2012	disease of bone structure, osteoporosis, spinal cord injury	Thomas J. Schnitzer	Completed	No outcome recorded
Phase 4	NCT00887354	Apr 2009 → Aug 2015	osteoporosis	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00557310	Nov 2007 → Oct 2010	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00446589	Jul 2006 → ?	osteoporosis	Papageorgiou General Hospital	Terminated	No outcome recorded Stop: Business
Phase 4	NCT00259298	Nov 2005 → Jul 2009	osteoporosis	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00239629	Sep 2005 → Jan 2007	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00079924	Nov 2004 → May 2007	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00532545	Apr 2003 → Apr 2004	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00191425	Aug 2002 → Nov 2005	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00035256	Oct 2001 → Jul 2005	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT02416271	Apr 2001 → May 2003	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded

Phase not applicable9 trials · 1 missed
—	NCT07242612	Oct 2025 → Mar 2026 overdue	postmenopausal osteoporosis	Khyber Medical University Peshawar	Recruiting	No outcome recorded
—	NCT05866029	May 2023 → Sep 2026 overdue	osteoporosis	Peking Union Medical College Hospital	Recruiting	No outcome recorded
—	NCT03770338	Mar 2019 → Mar 2026 overdue	osteoporosis	The University of Hong Kong	Active not recruiting	No outcome recorded
—	NCT02563353	Nov 2015 → Nov 2018	osteoporosis	Odense University Hospital	Completed	Mixed
—	NCT02440581	Jul 2015 → Jun 2021	chronic renal failure syndrome	Hartmut Malluche, MD	Completed	Missed primary
—	NCT01760798	Jan 2012 → Jun 2014	osteoporosis	Post Graduate Institute of Medical Education and Research, Chandigarh	Unknown	No outcome recorded
—	NCT00754442	Feb 2007 → Aug 2008	non-renal secondary hyperparathyroidism	University of Maryland, Baltimore	Completed	No outcome recorded
—	NCT00365924	Dec 2006 → Apr 2008	osteoporosis	Pfizer	Completed	No outcome recorded
—	NCT00347737	Jun 2006 → May 2008	osteoporosis	Leland Graves III, MD	Withdrawn	No outcome recorded
Comparator or background therapy50 trials
Phase 1	NCT05164614 Comparator	Feb → Oct 2022	—	RANI Therapeutics	Completed	No outcome recorded
Phase 1	NCT01913834 Comparator	Sep 2013 → Aug 2014	osteoporosis	Nottingham University Hospitals NHS Trust	Unknown	No outcome recorded
Phase 1	NCT02202603 Comparator	Jul 2011 → Aug 2013	—	Entera Bio Ltd.	Completed	No outcome recorded
Phase 1	NCT01224717 Comparator	Sep 2010 → Apr 2011	postmenopausal osteoporosis	Novartis	Completed	No outcome recorded
Phase 1	NCT02223416 Comparator	? → Jan 2015	—	Gedeon Richter Plc.	Completed	No outcome recorded
Phase 1/2	NCT03720886 Comparator	Oct 2018 → May 2020	postmenopausal osteoporosis	Shenzhen Salubris Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT05018637 Background	Sep 2020 → Dec 2022	osteoporosis, vertebral disorder	Inbo Han	Unknown	No outcome recorded
Phase 2	NCT03702140 Comparator	Oct 2018 → Oct 2023	osteoporosis	Shinshu University	Unknown	No outcome recorded
Phase 2	NCT03072147 Comparator	May 2017 → Sep 2022	osteoarthritis, knee	Christopher Ritchlin	Completed	No outcome recorded
Phase 2	NCT02023411 Comparator	Jan 2014 → Dec 2018	neurogenic arthropathy	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 2	NCT01440803 Comparator	Aug 2012 → Jan 2018	premenopausal osteoporosis	Elizabeth Shane	Completed	No outcome recorded
Phase 2	NCT01604057 Comparator	Nov 2011 → Jul 2012	osteoporosis	Azelon Pharmaceuticals	Unknown	No outcome recorded
Phase 2	NCT01321723 Comparator	Feb → Oct 2011	postmenopausal osteoporosis	Unigene Laboratories Inc.	Completed	No outcome recorded
Phase 2	NCT01063504 Comparator	Feb 2010 → Jun 2013	osteoarthritis, knee	University Hospital, Linkoeping	Completed	No outcome recorded
Phase 2	NCT01011556 Comparator	Nov 2009 → Sep 2011	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00896532 Comparator	Jun 2009 → Feb 2011	postmenopausal osteoporosis	Amgen	Completed	Met primary
Phase 2	NCT00759772 Comparator	Sep 2008 → Feb 2016	anorexia nervosa, osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00743782 Comparator	Aug 2008 → Apr 2014	autoimmune polyendocrine syndrome type 1, autosomal dominant hypocalcemia 1	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 2	NCT00624481 Comparator	Mar 2008 → Apr 2009	osteoporosis	Nastech Pharmaceutical Company, Inc.	Withdrawn	No outcome recorded
Phase 2	NCT00489918 Comparator	Jun 2007 → Apr 2008	osteoporosis	Zosano Pharma Corporation	Completed	No outcome recorded
Phase 2	NCT00471237 Comparator	May 2007 → Dec 2008	osteoporosis	GlaxoSmithKline	Terminated	Met primary
Phase 2	NCT00542425 Comparator	Apr 2007 → Jun 2009	osteoporosis	Radius Health, Inc.	Completed	Met primary
Phase 2	NCT00005006 Comparator	Sep 1987 → Feb 2003	osteoporosis	Helen Hayes Hospital	Completed	No outcome recorded
Phase 3	NCT06898060 Comparator	Jun 2025 → May 2027 expected	postmenopausal osteoporosis	Qilu Pharmaceutical Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 3	NCT02091492 Comparator	Jun 2014 → Sep 2015	osteoporosis	Medical University of Vienna	Withdrawn	No outcome recorded
Phase 3	NCT01896011 Comparator	Jul 2013 → Dec 2021	—	University Health Network, Toronto	Completed	No outcome recorded
Phase 3	NCT01796301 Comparator	Jan 2013 → May 2015	postmenopausal osteoporosis	Amgen	Completed	Met primary
Phase 3	NCT01343004 Comparator	Apr 2011 → Oct 2014	postmenopausal osteoporosis	Radius Health, Inc.	Completed	Met primary
Phase 3	NCT00577863 Background	Jan → May 2008	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00439244 Comparator	Dec 2006 → Feb 2009	osteoporosis	Novartis	Completed	No outcome recorded
Phase 3	NCT01611571 Comparator	Dec 2003 → Nov 2011	osteoporosis	Columbia University	Completed	No outcome recorded
Phase 3	NCT00542984 Comparator	Aug 2003 → Nov 2004	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00543218 Comparator	Dec 2002 → Jun 2004	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT06558188 Comparator	Feb 2025 → Nov 2027 expected	postmenopausal osteoporosis	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 4	NCT04589819 Comparator	Dec 2022 → Dec 2026 expected	—	University of South Carolina	Enrolling by invitation	No outcome recorded
Phase 4	NCT05151484 Comparator	Mar 2022 → Jan 2027 expected	osteoporosis	Madhumathi Rao	Active not recruiting	No outcome recorded
Phase 4	NCT04026256 Comparator	Sep 2019 → Apr 2022	postmenopausal osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT03472846 Comparator	Mar 2017 → Sep 2022	postmenopausal osteoporosis, type 2 diabetes mellitus	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT03735537 Comparator	Nov 2016 → Feb 2025	osteogenesis imperfecta	University of Edinburgh	Completed	No outcome recorded
Phase 4	NCT02176382 Comparator	Aug 2014 → Feb 2020	postmenopausal osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT01750086 Comparator	Jan 2013 → Apr 2014	postmenopausal osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT01734824 Comparator	May 2012 → Sep 2015	bone marrow disorder, bone remodeling disease	Medical University of Vienna	Suspended	No outcome recorded
Phase 4	NCT01166958 Comparator	Sep 2010 → Nov 2012	osteoporosis	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 4	NCT01153425 Comparator	Jul 2008 → Dec 2012	osteoporosis	University of Pennsylvania	Completed	No outcome recorded
Phase 4	NCT01535027 Comparator	Mar 2006 → Dec 2012	osteoporosis	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT00131469 Comparator	Jun 2005 → Jan 2011	osteogenesis imperfecta	Oregon Health and Science University	Completed	No outcome recorded
—	NCT04669782 Background	Nov 2020 → Jul 2024	osteoporosis	University of Milano Bicocca	Terminated	No outcome recorded Stop: Enrollment
—	NCT01656629 Comparator	Aug 2012 → Jun 2014	osteoporosis	Johns Hopkins University	Terminated	No outcome recorded Stop: Business
—	NCT01309399 Comparator	Aug 2010 → Nov 2014	osteoporosis	Health Research, Inc.	Completed	No outcome recorded
—	NCT00594906 Comparator	Jan 2008 → Jul 2012	—	University of Rochester	Terminated	No outcome recorded Stop: Enrollment

News releases announcing trial results or a regulatory action · 47

Date	Issuer	Release
2026-06-22	Entera Bio Ltd.	Regulatory Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis enterabio.com ↗ The FDA feedback is in response to a Clinical Amendment submitted by Entera to its Investigational New Drug (IND) application, as announced in March 2026.
2026-06-15	Entera Bio Ltd.	Results ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) enterabio.com ↗ Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass
2026-03-04	Entera Bio Ltd.	Regulatory Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis enterabio.com ↗ Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced the submission to the U.S. Food and Drug Administration (FDA) of a clinical amendment providing a streamlined Phase 3 protocol, statistical analysis plan (SAP), and open-label extension synopsis to the Company’s Investigational New Drug (IND) 505(b)(2) submission, to evaluate EB613 (Oral PTH(1-34), teriparatide).
2025-12-15	Amphastar Pharmaceuticals, Inc.	Regulatory Amphastar Announces FDA Approval for Teriparatide Injection amphastar.com ↗ Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen.
2025-09-08	Entera Bio Ltd.	Results Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025 enterabio.com ↗ EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide
2025-07-28	Entera Bio Ltd.	Regulatory Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis enterabio.com ↗ the U.S. Food and Drug Administration (FDA) agreed with the Company’s proposal
2024-06-03	Entera Bio Ltd.	Results Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024 enterabio.com ↗ Significant systemic exposure was reported following both administrations of EB612 tablets.
2023-11-17	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S. tevapharm.com ↗ Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States.
2023-10-16	Entera Bio Ltd.	Results Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting enterabio.com ↗
2023-02-15	Entera Bio Ltd.	Regulatory Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis enterabio.com ↗
2022-12-06	RANI Therapeutics	Results Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study ranitherapeutics.com ↗ The study achieved all of its endpoints, with repeat doses of RT-102 being generally well tolerated and delivering drug with high reliability to participants via the RaniPill™ GO.
2022-11-14	Halcygen Pharmaceuticals Limited	Regulatory Stelis receives a positive recommendation from European Medicines Agency (EMA) granting market authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis strides.com ↗ Stelis receives a positive recommendation from European Medicines Agency (EMA) granting market authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis.
2022-11-10	Entera Bio Ltd.	Results Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022 enterabio.com ↗ These findings are consistent with the positive correlation between the change in lumbar spine BMD and EB613 dose after six months of treatment.
2022-10-06	Entera Bio Ltd.	Regulatory Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis enterabio.com ↗ The FDA also agreed that Total Hip Bone Mineral Density (BMD) could serve as the primary endpoint for the registrational study of EB613 in post-menopausal osteoporosis patients.
2022-09-12	Entera Bio Ltd.	Results Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting enterabio.com ↗ These new analyses of blood hPTH concentration shortly after a dose of oral EB613 tablets confirm a strong, statistically significant correlation between mean blood level and the dose of EB613 taken.
2022-08-10	RANI Therapeutics	Results Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis ranitherapeutics.com ↗ specifically RT-102 delivered PTH with between 300-400% greater bioavailability than subcutaneous Forteo® (teriparatide) in the study.
2022-07-18	Entera Bio Ltd.	Regulatory Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position enterabio.com ↗ FDA re-confirmed that with a well-designed BMD study, EB613 approval would not require a fracture study
2022-02-20	MinaPharm Pharmaceuticals	Results Minapharm Pharmaceuticals Announces the Successful Completion of its Phase 1 Clinical Trial in Europe for its Recombinant Teriparatide, Bonosome. minapharm.com ↗ The primary endpoints of demonstrating pharmacokinetic equivalence between Bonosome rDNA and the reference product FORSTEO® were reached and were within the biosimilarity ranges of 80% to 125%.
2021-10-28	Entera Bio Ltd.	Results Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs enterabio.com ↗ The researchers concluded that an appropriate combination of these different technological approaches considerably contributes to the efficient oral delivery of a number of biological macromolecules.
2021-08-16	Entera Bio Ltd.	Results Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates enterabio.com ↗ The most important BMD endpoint — change in lumbar spine BMD after 6 months — was met in the double-blind, dose-ranging, placebo-controlled study in 161 postmenopausal female subjects with osteoporosis or with low BMD.
2021-08-02	Entera Bio Ltd.	Results Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting enterabio.com ↗ The Phase 2 clinical trial of EB613, an oral formulation of human parathyroid hormone (PTH) (1-34), for the treatment of osteoporosis met its primary and key secondary endpoints, positioning it to be the first oral bone building (anabolic) product to treat osteoporosis patients.
2021-05-20	Entera Bio Ltd.	Results Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates enterabio.com ↗ The study met its primary 3-month endpoint.
2021-03-18	Entera Bio Ltd.	Results Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020 enterabio.com ↗ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial
2021-03-15	MinaPharm Pharmaceuticals	Regulatory Minapharm Announces the First of its Kind Approval from the German Regulatory Authority BfArM to Conduct a Phase 1 Clinical Trial of a Biosimilar Developed in Egypt and the Region minapharm.com ↗ Minapharm Pharmaceuticals S.A.E has announced today that the German regulatory authority BfArM (Federal Institute for Drugs and Medical Devices) approved a phase 1 clinical trial for its biosimilar teriparatide in Germany.
2021-03-11	Entera Bio Ltd.	Results Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data enterabio.com ↗ The trial’s primary endpoint was met - the complete 3-month results from the trial showed a significant increase in the P1NP biomarker in the 2.5 mg dose group after 3 months of treatment (P <0.04) as compared to placebo.
2021-02-25	Entera Bio Ltd.	Results Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research enterabio.com ↗ The Phase 2a study demonstrated the safety and tolerability of EB612 administered four times daily for 16 weeks to patients with HypoPT.
2020-08-20	Entera Bio Ltd.	Results Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results enterabio.com ↗ Based on the 6-month data, EB613 generated a mean placebo adjusted increase in lumbar spine BMD of 2.15% (p = 0.08) for the 14 patients in the 1.5 mg treatment arm, as compared to 16 patients in the placebo arm.
2020-05-21	Entera Bio Ltd.	Results Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results enterabio.com ↗ The study demonstrated statistically significant effects on the P1NP biomarker after one month of treatment (p<0.001) as compared to placebo, and meaningful increases at months two and three as compared to placebo with the highest EB613 dose (1.5 mg).
2019-05-30	Alvogen Korea	Regulatory Alvogen and Pfenex Announce Acceptance of MAA for PF708 alvogen.com ↗ Alvogen and Pfenex Inc. (NYSE American: PFNX) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) submitted for PF708 (Teriparatide).
2017-11-09	Eli Lilly and Company	Results New Data on FORTEO® (teriparatide [rDNA origin] injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis lilly.com ↗ Results from the study's primary endpoint showed that at 24 months, fewer patients taking FORTEO® had new vertebral fractures as compared to patients taking risedronate (5.4% vs. 12.0%, p <0.0001).
2016-04-01	Amgen	Results Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide amgen.com ↗ At the hip, patients transitioning to teriparatide showed either no gains or significant decreases in these parameters.
2015-10-12	Amgen	Results New Exploratory Analysis Showed Romosozumab Increased Estimated Bone Strength More Than Teriparatide amgen.com ↗ The small exploratory sub-study data showed that, at month 12, the investigational bone-forming agent romosozumab increased estimated bone strength (percent change from baseline) at the spine and hip more than open-label teriparatide in postmenopausal women with low bone mass.
2015-09-01	Amgen	Results Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide amgen.com ↗ The study (NCT01796301) met the primary endpoint, demonstrating a statistically significant difference in favor of romosozumab in the percent change of total hip bone mineral density (measured by DXA) through month 12.
2013-05-29	Eli Lilly and Company	Results New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis lilly.com ↗ Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) compared to risedronate in men with glucocorticoid-induced osteoporosis.
2012-10-15	Eli Lilly and Company	Results Lilly Announces New Data Further Exploring Mechanistic Differences Between FORTEO® (teriparatide [rDNA origin] injection) and Zoledronic Acid lilly.com ↗ Eli Lilly and Company (NYSE: LLY) today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months in postmenopausal women with osteoporosis, based on additional analysis of data from the SHOTZ trial.
2012-08-07	Eli Lilly and Company	Results Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures lilly.com ↗ At six months, more than half of patients in both treatment groups reported a 30 percent or greater reduction in worst back pain (FORTEO — 59.2 percent, risedronate — 57.4 percent; p=0.64).
2011-09-19	Eli Lilly and Company	Results Research Suggests FORTEO® Significantly Increases Bone Strength lilly.com ↗ Researchers concluded that FORTEO increased vertebral and femoral strength in the spine and hip bones compared to baseline.
2011-09-19	Eli Lilly and Company	Results New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid lilly.com ↗ Dynamic indices of bone formation, including mineralizing surface/bone surface (MS/BS) and bone formation rate (BFR), were significantly higher in women treated with FORTEO than in women treated with zoledronic acid at six months.
2009-07-23	Eli Lilly and Company	Regulatory /C O R R E C T I O N -- Eli Lilly and Company/ lilly.com ↗ the U.S. Food and Drug Administration (FDA) has approved a new use for its osteoporosis drug FORTEO(R) [teriparatide (rDNA origin) injection]
2008-02-22	Eli Lilly and Company	Regulatory FORSTEO(R) Receives Positive Opinion from the European Committee for Medicinal Products for Human Use for the Treatment of Glucocorticoid-Induced Osteoporosis lilly.com ↗ Eli Lilly and Company (NYSE: LLY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion recommending approval of FORSTEO(R) (teriparatide [rDNA origin] injection) for the treatment of osteoporosis associated with sustained, systemic glucocorticoid therapy in women and men at increased risk for fracture.
2007-11-14	Eli Lilly and Company	Results FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis lilly.com ↗ In this head-to-head comparator study, the increase in lumbar spine BMD was significantly greater in patients receiving teriparatide compared with alendronate at 6, 12, and 18 months of treatment (p 0.001 at all time points).
2005-09-27	Eli Lilly and Company	Results Teriparatide Relies on More than Bone Mineral Density to Reduce Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis lilly.com ↗ A new data analysis of the Fracture Prevention Trial showed that increases in bone mineral density (BMD) account for 30 to 40 percent of the vertebral fracture risk reduction seen with teriparatide.
2005-08-08	Eli Lilly and Company	Results New Study Provides In-Depth Look at How Osteoporosis Treatments Function Within Bone lilly.com ↗ The study, which provides more in-depth information than previously available about these two treatments, found that both therapies increase bone mineral density (BMD), but to different degrees and through different means.
2004-10-04	Eli Lilly and Company	Results Analysis Showed Teriparatide Reduced Fracture Risk Independent of Bone Turnover lilly.com ↗ Data presented today at the 26th annual meeting of the American Society for Bone and Mineral Research (ASBMR) show that the ability of teriparatide to prevent fractures remained consistent regardless of pretreatment bone turnover status.
2004-10-03	Eli Lilly and Company	Results Number, Severity of Fractures Predicts Future Risk lilly.com ↗ These trends were not observed in women treated with FORTEO.
2004-06-16	Eli Lilly and Company	Results New Analysis Showed Early Patient Response to Forteo in Postmenopausal Women with Osteoporosis lilly.com ↗
2001-07-27	Eli Lilly and Company	Regulatory FDA Advisory Committee Recommends Approval of Lilly's FortéoTM for the Treatment of Osteoporosis in Postmenopausal Women lilly.com ↗

All press releases naming this drug 54 releases

Date	Issuer	Release
2026-06-22	Entera Bio Ltd.	Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis enterabio.com ↗
2026-06-15	Entera Bio Ltd.	ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) enterabio.com ↗
2026-03-04	Entera Bio Ltd.	Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis enterabio.com ↗
2025-12-15	Amphastar Pharmaceuticals, Inc.	Amphastar Announces FDA Approval for Teriparatide Injection amphastar.com ↗
2025-09-08	Entera Bio Ltd.	Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025 enterabio.com ↗
2025-07-28	Entera Bio Ltd.	Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis enterabio.com ↗
2024-06-03	Entera Bio Ltd.	Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024 enterabio.com ↗
2023-11-17	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S. tevapharm.com ↗
2023-10-16	Entera Bio Ltd.	Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting enterabio.com ↗
2023-02-15	Entera Bio Ltd.	Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis enterabio.com ↗
2022-12-06	RANI Therapeutics	Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study ranitherapeutics.com ↗
2022-11-14	Halcygen Pharmaceuticals Limited	Stelis receives a positive recommendation from European Medicines Agency (EMA) granting market authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis strides.com ↗
2022-11-10	Entera Bio Ltd.	Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022 enterabio.com ↗
2022-10-06	Entera Bio Ltd.	Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis enterabio.com ↗
2022-09-12	Entera Bio Ltd.	Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting enterabio.com ↗
2022-08-10	RANI Therapeutics	Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis ranitherapeutics.com ↗
2022-07-18	Entera Bio Ltd.	Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position enterabio.com ↗
2022-02-20	MinaPharm Pharmaceuticals	Minapharm Pharmaceuticals Announces the Successful Completion of its Phase 1 Clinical Trial in Europe for its Recombinant Teriparatide, Bonosome. minapharm.com ↗
2021-10-28	Entera Bio Ltd.	Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs enterabio.com ↗
2021-08-16	Entera Bio Ltd.	Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates enterabio.com ↗
2021-08-02	Entera Bio Ltd.	Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting enterabio.com ↗
2021-05-20	Entera Bio Ltd.	Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates enterabio.com ↗
2021-03-18	Entera Bio Ltd.	Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020 enterabio.com ↗
2021-03-15	MinaPharm Pharmaceuticals	Minapharm Announces the First of its Kind Approval from the German Regulatory Authority BfArM to Conduct a Phase 1 Clinical Trial of a Biosimilar Developed in Egypt and the Region minapharm.com ↗
2021-03-11	Entera Bio Ltd.	Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data enterabio.com ↗
2021-02-25	Entera Bio Ltd.	Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research enterabio.com ↗
2020-12-10	Entera Bio Ltd.	Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis enterabio.com ↗
2020-08-20	Entera Bio Ltd.	Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results enterabio.com ↗
2020-05-21	Entera Bio Ltd.	Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results enterabio.com ↗
2019-10-21	Alvogen Korea	Alvogen announces exclusive commercialization agreements in South Korea, Israel and Canada for Teriparatide (PF708) alvogen.com ↗
2019-05-30	Alvogen Korea	Alvogen and Pfenex Announce Acceptance of MAA for PF708 alvogen.com ↗
2018-06-12	Alvogen Korea	Alvogen and Pfenex enter into U.S. agreement for commercialization of PF708 alvogen.com ↗
2017-11-09	Eli Lilly and Company	New Data on FORTEO® (teriparatide [rDNA origin] injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis lilly.com ↗
2016-04-01	Amgen	Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide amgen.com ↗
2015-10-12	Amgen	New Exploratory Analysis Showed Romosozumab Increased Estimated Bone Strength More Than Teriparatide amgen.com ↗
2015-09-01	Amgen	Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide amgen.com ↗
2013-05-29	Eli Lilly and Company	New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis lilly.com ↗
2012-10-15	Eli Lilly and Company	Lilly Announces New Data Further Exploring Mechanistic Differences Between FORTEO® (teriparatide [rDNA origin] injection) and Zoledronic Acid lilly.com ↗
2012-08-07	Eli Lilly and Company	Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures lilly.com ↗
2011-09-19	Eli Lilly and Company	Research Suggests FORTEO® Significantly Increases Bone Strength lilly.com ↗
2011-09-19	Eli Lilly and Company	New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid lilly.com ↗
2011-03-17	Eli Lilly and Company	Lilly Announces Important Action Regarding Recall of Alcohol Prep Pads Made by Triad Group Included in Forteo Starter Kits lilly.com ↗
2010-10-14	Eli Lilly and Company	New FORTEO(R) and EVISTA(R) Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research lilly.com ↗
2009-07-23	Eli Lilly and Company	/C O R R E C T I O N -- Eli Lilly and Company/ lilly.com ↗
2008-10-15	Eli Lilly and Company	Lilly Launches New FORTEO Delivery Device lilly.com ↗
2008-02-22	Eli Lilly and Company	FORSTEO(R) Receives Positive Opinion from the European Committee for Medicinal Products for Human Use for the Treatment of Glucocorticoid-Induced Osteoporosis lilly.com ↗
2007-11-14	Eli Lilly and Company	FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis lilly.com ↗
2005-09-27	Eli Lilly and Company	Teriparatide Relies on More than Bone Mineral Density to Reduce Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis lilly.com ↗
2005-09-26	Eli Lilly and Company	New Study to Give Insight into Teriparatide use in the Real World Setting lilly.com ↗
2005-08-08	Eli Lilly and Company	New Study Provides In-Depth Look at How Osteoporosis Treatments Function Within Bone lilly.com ↗
2004-10-04	Eli Lilly and Company	Analysis Showed Teriparatide Reduced Fracture Risk Independent of Bone Turnover lilly.com ↗
2004-10-03	Eli Lilly and Company	Number, Severity of Fractures Predicts Future Risk lilly.com ↗
2004-06-16	Eli Lilly and Company	New Analysis Showed Early Patient Response to Forteo in Postmenopausal Women with Osteoporosis lilly.com ↗
2001-07-27	Eli Lilly and Company	FDA Advisory Committee Recommends Approval of Lilly's FortéoTM for the Treatment of Osteoporosis in Postmenopausal Women lilly.com ↗

Evidence & citations 19 cited values

Every value below carries the sentence it was read from. 154 sources stand behind the page.

Field	Value	Cited text
Known as	Teriparatide	“This study is a Phase 1, multi-center, 2-part, subject- and investigator-blind, randomized, placebo-controlled, multiple dose study of transdermal teriparatide (80-µg dose) in...” NCT01250145 ↗ 131 “Teriparatide (TP), a recombinant human parathyroid hormone (PTH 1-34), is a bone forming agent mainly used to treat osteoporotic patients with high risk of osteoporotic fracture.” NCT04241211 ↗ “Teriparatide (recombinant human parathyroid hormone [1-34]) increases bone formation and improves bone microarchitecture, thereby reducing the risk of fractures.” PMID 18822620 ↗ Jun 2008 “This longitudinal clinical trial assessed outcomes of periodontal surgery and teriparatide administration in vitamin-D-sufficient and -insufficient individuals.” PMID 21555774 ↗ May 2011 “Teriparatide is a drug currently prescribed for some osteoporosis patients by their doctor to be taken by injection.” NCT01913834 ↗ “Teriparatide Injection daily formulation administered for 2 weeks, followed by SAL056 for 6 weeks.” NCT07579936 ↗ “The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab” NCT02130973 ↗ “the sub-cutaneous form of teriparatide, the active ingredient in PTH134” NCT01224717 ↗ “Teriparatide (Forsteo®), 20µg s.c. daily for 24 months.” NCT01801397 ↗ “transdermal administration of teriparatide acetate” NCT01551602 ↗ “Forsteo (Teriparatide)” NCT01321723 ↗ Show 121 more sources
Known as	AK159	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01935479 ↗
Known as	Forsteo	“Patients were administered 20mcg of TP (Forsteo) subcutaneously once a day from the day between before 3months to after 3months about surgery.” NCT04241211 ↗ 6 “in comparison to Forsteo®, the sub-cutaneous form of teriparatide” NCT01224717 ↗ “Teriparatide (Forsteo) 20 micrograms daily during four weeks” NCT01105832 ↗ “Teriparatide (Forsteo®), 20µg s.c. daily for 24 months.” NCT01801397 ↗ NCT02955056 ↗ NCT01321723 ↗ NCT07497503 ↗
Known as	Forteo	“Each side will be grafted with Bio-Oss® or Bio-Oss® combined with 1 dose (20 µg) of teriparatide (Forteo®).” NCT06061354 ↗ 13 “The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab” NCT02130973 ↗ “teriparatide (Forteo) has been shown to improve bone mass and microarchitecture” NCT01440803 ↗ “has been approved for the treatment of osteoporosis as FORTEO by Eli Lilly” NCT00277706 ↗ “daily injections with 20 µg teriparatide (PTH 1-34 (Forteo)) for 4 weeks” PMID 26179771 ↗ Jul 2015 “30 participants will receive teriparatide (Forteo) injection pens.” NCT00594906 ↗ “Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months” NCT02025179 ↗ “two teriparatide products (PF708 and Forteo)” NCT02656810 ↗ “"Teriparatide", "Forteo® or Teribon"” NCT03702140 ↗ “Drug: Teriparatide (Forteo)” NCT03002428 ↗ “Teriparatide Forteo” NCT01945788 ↗ Show 3 more sources
Known as	hPTH 1-34	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00086619 ↗
Known as	Osteofortil	“Teriparatide Osteofortil” NCT01945788 ↗
Known as	Parathyroid Hormone (1-34)	“Oral administration of EnteraBio's Oral Parathyroid Hormone (1-34)” NCT02152228 ↗
Known as	PF708	“Drug: Teriparatide (PF708)” NCT03002428 ↗
Known as	PTH	“received Synthetic Human Parathyroid Hormone 1-34 (PTH) delivered through an insulin pump” NCT00743782 ↗
Known as	PTH 1-34	“Teriparatide or PTH 1-34 is a 34 amino acid peptide derived by recombinant DNA technology from the authentic sequence of human parathyroid hormone.” NCT03994172 ↗ 8 “Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women” PMID 24420643 ↗ Jun 2014 “an oral PTH (1-34) preparation produced by Entera Bio” NCT02152228 ↗ “Teriparatide (PTH 1-34)” NCT00697463 ↗ NCT00676312 ↗ NCT00018447 ↗ NCT00395538 ↗ NCT01224717 ↗ NCT00593177 ↗
Known as	rhPTH 1-34	“Teriparatide, rhPTH(1-34), produced in E. coli, using recombinant DNA technology, is identical to the 34-N-terminal amino acid sequence of endogenous human parathyroid hormone.” NCT04196855 ↗ 1 “standard treatment + Forsteo (rhPTH 1-34) during 4 weeks” NCT01105832 ↗
Known as	Synthetic Human Parathyroid Hormone 1-34	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00743782 ↗ 1 NCT00001304 ↗
Known as	Teribon	“"Teriparatide", "Forteo® or Teribon"” NCT03702140 ↗
Known as	Teribone	“56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.” NCT03720886 ↗
Known as	teriparatide acetate	“56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.” NCT03720886 ↗
Known as	TPTD	“In order to maximize the early anabolic effect with teriparatide (TPTD), and to avoid the development of tachyphylaxis to the continued daily administration of TPTD beyond 6...” NCT02130973 ↗ 7 “PURPOSE: To evaluate the effects of cyclic vs daily teriparatide treatment (TPTD) on volumetric bone mineral density (vBMD) and bone strength at the hip and spine in women who...” PMID 36410666 ↗ Nov 2022 “Treatment of osteoporosis with an anabolic agent, teriparatide [human PTH 1-34 (TPTD)], is effective in reducing incident fractures, but patient resistance to daily sc...” PMID 19858319 ↗ Oct 2009 “Teriparatide (TPTD) increases skeletal mass, bone turnover markers, and bone strength, but in vivo effects at individual skeletal sites have not been characterized.” PMID 19929434 ↗ May 2010 “INTRODUCTION: To determine if teriparatide (20 μg/day; TPTD) results in improved radiologic healing, reduced pain, and improved functional outcome vs placebo” PMID 34383100 ↗ Aug 2021 “Teriparatide (TPTD) or PTH 1-34 which will be obtained from commercial sources and given at 20 mcg daily, by SC injection.” NCT03994172 ↗ “human recombinant parathyroid hormone (hPTH) 1-34 (or teriparatide (TPTD))” NCT01440803 ↗ “Teriparatide (TPTD) 20mcg daily using Teriparatide Pen Injector” NCT03735537 ↗
Action	Restore	“therapeutic PTH replacement” NCT00001304 ↗
Modality	Protein / enzyme biologic	“79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months” PMID 24463451 ↗ Jan 2014
Route	Subcutaneous	“twice daily subcutaneous injections” NCT00001304 ↗